earnings
RN
NASDAQ · RNXT
RenovoRx, Inc.
Healthcare · Biotechnology
$1.32
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 2:25 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 36.39M
- P/E ratio
- -3.41
- Dividend yield
- 0.00%
- 52-week range
- $0.77 – $1.51
- Volume
- 233.27K
- Avg. volume
- 506.07K
Price performance
RNXT price history
1M range · 20 trading sessions · Daily adjusted prices
RNXT closed at $1.32 after 20 trading sessions, up 36.77% for the selected period.
- Last close
- $1.32
- Period change
- +36.77%
- Period low
- $0.90
- Period high
- $1.40
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.30 | $1.325 | $1.25 | $1.32 | 233.27K |
| Aug 20, 2026 | $1.29 | $1.35 | $1.23 | $1.32 | 381.18K |
| Aug 19, 2026 | $1.17 | $1.3372 | $1.15 | $1.315 | 582.34K |
| Aug 18, 2026 | $1.21 | $1.2686 | $1.12 | $1.17 | 498.97K |
| Aug 17, 2026 | $1.415 | $1.505 | $1.1799 | $1.20 | 1.22M |
| Aug 14, 2026 | $1.27 | $1.45 | $1.26 | $1.40 | 1.01M |
| Aug 13, 2026 | $1.12 | $1.30 | $1.12 | $1.26 | 993.81K |
| Aug 12, 2026 | $1.14 | $1.16 | $1.10 | $1.12 | 477.07K |
| Aug 11, 2026 | $1.16 | $1.20 | $1.12 | $1.15 | 361.52K |
| Aug 10, 2026 | $1.14 | $1.16 | $1.09 | $1.16 | 317.7K |
| Aug 7, 2026 | $1.17 | $1.20 | $1.10 | $1.12 | 317.83K |
| Aug 6, 2026 | $1.07 | $1.18 | $1.07 | $1.15 | 693.6K |
| Aug 5, 2026 | $1.06 | $1.0999 | $1.04 | $1.06 | 316.72K |
| Aug 4, 2026 | $0.9811 | $1.06 | $0.98 | $1.04 | 401.84K |
| Aug 3, 2026 | $0.9653 | $1.0999 | $0.95 | $1.06 | 703.84K |
| Jul 31, 2026 | $0.95 | $0.97 | $0.9234 | $0.9583 | 244.99K |
| Jul 30, 2026 | $0.91 | $0.9499 | $0.91 | $0.9412 | 113.57K |
| Jul 29, 2026 | $0.91 | $0.9296 | $0.8866 | $0.8981 | 127.62K |
| Jul 28, 2026 | $0.9325 | $0.9699 | $0.88 | $0.9073 | 219.74K |
| Jul 27, 2026 | $0.90 | $0.98 | $0.871 | $0.9651 | 868.8K |
Latest RNXT news
The latest Smart Investors Daily articles mentioning RNXT.
Stock researchCompany · Forecast
Loading stock research…